

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Various</b>				
Autoimmune; inflammation	Interferon- $\beta$ (IFN $\beta$ ); IFN- $\beta$ ); Na <sup>+</sup> /K <sup>+</sup> ATPase pump	<i>In vitro</i> studies suggest that cardiac glycosides could help to treat autoimmune and inflammatory diseases. In virus-infected cells, cardiac glycosides, which are known to inhibit the Na <sup>+</sup> /K <sup>+</sup> ATPase pump, led to decreased viral-induced expression of proinflammatory IFN- $\beta$ compared with no treatment. Next steps include testing cardiac glycosides in mouse models of inflammatory and autoimmune disease.	Patent application filed for inflammatory and autoimmune disease; available for licensing from Harvard University	Ye, J. <i>et al. Nat. Chem. Biol.</i> ; published online Nov. 14, 2010; doi:10.1038/nchembio.476 <b>Contact:</b> Tom Maniatis, Columbia University College of Physicians and Surgeons, New York, N.Y. e-mail: <a href="mailto:tm2472@mail.cumc.columbia.edu">tm2472@mail.cumc.columbia.edu</a>
<p><b>SciBX 3(46); doi:10.1038/scibx.2010.1394</b>  <b>Published online Dec. 2, 2010</b></p>				